Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Since the GLP-1 drugs, including Mounjaro, Ozempic and Wegovy, were licensed, there have been hundreds of reported cases of ...

Both Wegovy and Ozempic are semaglutide – a drug that first entered the US market in 2017 as a diabetes medication. It was ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Mounjaro has been approved for both type 2 diabetes and weight loss; however, access will be limited by strict eligibility ...

While real-time data on how Indians are responding to these drugs is still emerging, experts say that sustained weight loss ...

WEIGHT loss jabs may also help ward off dementia, a new study suggests. Researchers found that semaglutide – the active ...

However, if you're planning to ask your GP to prescribe it, are you actually eligible and do you meet the very specific ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users ...